RecallRadar

FDA Drug recall D-1289-2022

Testosterone Gel 1% (25mg testosterone/2.5g of gel) 2.5 g per unit dose, Rx Only, 30 unit-dose packets per box

On 2022-08-03 the FDA classified a Class II recall of Testosterone Gel 1% (25mg testosterone/2.5g of gel) 2.5 g per unit dose, Rx Only, 30 unit-dose packets per box by Teva Pharmaceuticals Usa, citing superpotent Drug: Out of specification assay result was obtained during stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1289-2022
ClassificationClass II
Statusterminated
Initiated2022-06-29
Published2022-08-03
Last updated2026-09-13 11:52 UTC
CompanyTeva Pharmaceuticals Usa
DistributionUS

Product

Testosterone Gel 1% (25mg testosterone/2.5g of gel) 2.5 g per unit dose, Rx Only, 30 unit-dose packets per box. Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, US 84108, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA, Sachet NDC 0591-3216-17, Carton NDC 0591-3216-30

Reason

Superpotent Drug: Out of specification assay result was obtained during stability testing.

Identifiers

ndc0591-2921-18
ndc0591-2921-02
ndc0591-3216-17
ndc0591-3216-30
ndc0591-3217-26
ndc0591-3217-30
code_infoLot: 1403180, EXP. 10/2022

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1289-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.